Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.
Urinary kallikrein excretion is reduced in patients with hypertension of unknown etiology. In addition, the excretion of this renal, kinin-forming enzyme was found to be elevated in hypertensive patients with primary aldosteronism. Aldosterone regulates kallikrein excretion, as normal subjects show increased kallikrein excretion in response to a low sodium intake, high potassium intake, or the synthetic mineralocorticoid, fludrocortisone, whereas kallikrein excretion falls during treatment with spironolactone. The relationship between kallikrein excretion and aldosterone activity may directly reflect the intrarenal activity of the kallikrein-kinin system, as determined by studies of kallikrein levels from isolated renal cells or of plasma kinin levels in man in response to postural changes or saline loads. Some patients with essential hypertension do not show a normal increase in kallikrein excretion in response to low dietary sodium intake despite an apparently normal aldosterone response, suggesting that there may be a defect in the renal kallikrein-kinin system in these patients. Whether these findings are of pathogenetic significance in human hypertensive disease remains to be determined.
D005438:Fludrocortisone / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000652:urine*; D007610:Kallikreins / Q000652:urine*; D008901:Mineralocorticoids / Q000494:pharmacology*; D012964:Sodium / Q000494:pharmacology; D013148:Spironolactone / Q000494:pharmacology
D008901:Mineralocorticoids; D013148:Spironolactone; D012964:Sodium; D007610:Kallikreins; D005438:Fludrocortisone